X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (866) 866
type 2 diabetes (743) 743
dpp-4 inhibitor (716) 716
diabetes mellitus, type 2 - drug therapy (680) 680
dpp-4 inhibitors (656) 656
diabetes (560) 560
endocrinology & metabolism (544) 544
male (513) 513
sitagliptin (441) 441
dipeptidyl-peptidase iv inhibitors - therapeutic use (439) 439
hypoglycemic agents - therapeutic use (401) 401
female (388) 388
glucagon-like peptide-1 (383) 383
animals (349) 349
pharmacology & pharmacy (343) 343
middle aged (340) 340
metformin (337) 337
glucose (326) 326
double-blind (306) 306
dipeptidyl peptidase-4 inhibitor (296) 296
diabetes mellitus (287) 287
dpp-4 (287) 287
aged (269) 269
glycemic control (265) 265
vildagliptin (260) 260
type 2 diabetes mellitus (253) 253
treatment outcome (252) 252
glp-1 (243) 243
dipeptidyl-peptidase iv inhibitors - pharmacology (239) 239
insulin (237) 237
safety (231) 231
diabetes mellitus, type 2 - blood (216) 216
linagliptin (215) 215
dipeptidyl peptidase-4 inhibitors (203) 203
hypoglycemic agents (203) 203
adult (201) 201
type-2 diabetes-mellitus (193) 193
efficacy (189) 189
dipeptidyl-peptidase iv inhibitors - adverse effects (188) 188
hypoglycemic agents - adverse effects (182) 182
adamantane - analogs & derivatives (173) 173
blood glucose - drug effects (173) 173
drug therapy (172) 172
diabetes therapy (168) 168
hypoglycemic agents - administration & dosage (167) 167
analysis (166) 166
blood glucose - metabolism (165) 165
dextrose (164) 164
drug therapy, combination (162) 162
care and treatment (161) 161
internal medicine (160) 160
glucagon (157) 157
beta-cell function (154) 154
saxagliptin (151) 151
dipeptidyl-peptidase iv inhibitors - administration & dosage (148) 148
dipeptidyl peptidase 4 - metabolism (147) 147
hypoglycemic agents - pharmacology (141) 141
mice (141) 141
peptidase (141) 141
medicine & public health (139) 139
mellitus (137) 137
hypoglycemia (135) 135
incretin (131) 131
double-blind method (129) 129
improves glycemic control (129) 129
clinical trials (126) 126
glycated hemoglobin a - metabolism (125) 125
medicine, general & internal (125) 125
rats (124) 124
sitagliptin phosphate (124) 124
diabetes mellitus, type 2 - complications (120) 120
review (119) 119
pharmacokinetics (118) 118
risk factors (117) 117
research (115) 115
peptides (112) 112
hyperglycemia (110) 110
therapy (110) 110
dpp‐4 inhibitor (109) 109
oxidative stress (108) 108
insulin resistance (107) 107
metformin - therapeutic use (107) 107
incretins (105) 105
chemistry, medicinal (104) 104
medicine, research & experimental (103) 103
mortality (102) 102
biochemistry & molecular biology (101) 101
cardiac & cardiovascular systems (101) 101
diabetes mellitus, type 2 - metabolism (100) 100
cardiovascular outcomes (99) 99
glp-1 receptor agonists (99) 99
liraglutide (97) 97
type-2 (97) 97
adamantane - therapeutic use (96) 96
dipeptidyl peptidase-4 (96) 96
dpp-4 inhibition (96) 96
glycosylated hemoglobin (94) 94
alogliptin (93) 93
risk (92) 92
inflammation (90) 90
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1785) 1785
Chinese (82) 82
French (24) 24
Japanese (24) 24
German (20) 20
Russian (17) 17
Czech (11) 11
Korean (8) 8
Spanish (8) 8
Polish (4) 4
Hungarian (2) 2
Portuguese (2) 2
Slovak (2) 2
Arabic (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, obesity & metabolism, ISSN 1463-1326, 2017, Volume 20, Issue 2, pp. 344 - 351
Aims To compare the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor dapagliflozin with dipeptidyl peptidase‐4 (DPP‐4... 
cardiovascular disease | DPP‐4 inhibitor | type 2 diabetes | diabetes complications | hypoglycaemia | dapagliflozin | DPP-4 inhibitor | SEVERE HYPOGLYCEMIA | MONOTHERAPY | HEART-FAILURE | PREVALENCE | COMBINATION | METFORMIN TREATMENT | INSULIN | DRUGS | ENDOCRINOLOGY & METABOLISM | DPP-4 INHIBITORS | OUTCOMES | Diabetic Cardiomyopathies - ethnology | Cardiovascular Diseases - ethnology | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Incidence | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - ethnology | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Female | Glucosides - therapeutic use | Diabetic Angiopathies - prevention & control | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Diabetic Angiopathies - ethnology | Sweden - epidemiology | Diabetic Cardiomyopathies - epidemiology | Norway - epidemiology | Denmark - epidemiology | Membrane Transport Modulators - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Type 2 diabetes | Heart | Complications and side effects | Comorbidity | Atrial fibrillation | Glucose | Comparative analysis | Risk factors | Heart attack | Dextrose | Diabetes therapy | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Heart attacks | Peptidase | Mortality | Diabetes mellitus | Hypoglycemia | Patients | Fibrillation | Sodium | Diabetes | Cardiovascular diseases | Health risk assessment | Diabetes mellitus (non-insulin dependent) | Heart diseases | Original
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 23, pp. 2628 - 2639
BACKGROUND Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i... 
heart failure | SEVERE HYPOGLYCEMIA | SULFONYLUREA | death | INITIATION | SGLT-2 inhibitor | diabetes mellitus | sodium glucose cotransporter-2 inhibitors | ALL-CAUSE MORTALITY | ORGANIZATION | JAPANESE HOSPITAL DATABASE | ASIA | LOWER RISK | DPP-4 INHIBITORS | observational studies | CARDIAC & CARDIOVASCULAR SYSTEMS | INSULIN | OUTCOMES | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Male | Diabetes Mellitus, Type 2 - epidemiology | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Internationality | Cardiovascular Diseases - blood | Cardiovascular Diseases - epidemiology | Adult | Female | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Electronic Health Records | Cohort Studies | Glucose | Chemical vapor deposition | Analysis | Dextrose | Heart | Drugs | Laboratories | Identification methods | Personal health | Clinical trials | Medical records | Subgroups | Matching | Confidence intervals | Databases | Risk assessment | Diuretics | Population | Diabetes mellitus (non-insulin dependent) | Heart diseases | Heart failure | Health insurance | Stroke | Payment systems | Diabetes mellitus | Mortality | Health risks | Patients | Prescription drugs | Hospitals | Inhibitors | Sodium | Death | Diabetes | Clinical medicine | Cardiovascular diseases | Pharmaceuticals
Journal Article
Cardiovascular diabetology, ISSN 1475-2840, 07/2014, Volume 13, Issue 1, pp. 110 - 110
Background: Alpha glucosidase inhibitor (GI) attenuates postprandial hyperglycemia (PPH... 
Dipeptidyl peptidase 4 (DPP-4) inhibitors | Endothelial function | Flow-mediated dilatation | Alpha glucosidase inhibitor | CD34 | PROGENITOR CELLS | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | MYOCARDIAL-INFARCTION | VASCULAR-DISEASE | FLOW-MEDIATED VASODILATION | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | CARDIOVASCULAR-DISEASE | JAPANESE PATIENTS | CORONARY-ARTERY-DISEASE | Prospective Studies | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Endothelium, Vascular - drug effects | Glycoside Hydrolase Inhibitors - therapeutic use | Male | Pyrazines - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Endothelium, Vascular - physiology | Young Adult | Inositol - therapeutic use | Aged, 80 and over | Adult | Female | Sitagliptin Phosphate | Triazoles - therapeutic use | Inositol - pharmacology | Glycoside Hydrolase Inhibitors - pharmacology | Inositol - analogs & derivatives | Triazoles - pharmacology | Diabetes Mellitus, Type 2 - diagnosis | Aged | Diabetes Mellitus, Type 2 - drug therapy | Pyrazines - pharmacology | Urine | Oxidative stress | Peptides | Internal medicine | Colleges & universities | Cardiovascular disease | Dentistry | Medicine | Hyperglycemia | Hospitals | Coronary vessels | Diabetes | Acute coronary syndromes | Drug dosages | Pharmaceutical sciences | Pharmaceuticals
Journal Article
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2012, Volume 167, Issue 2, pp. 451 - 457
Journal Article
Diabetes care, ISSN 1935-5548, 2016, Volume 39, Issue 1, pp. 139 - 148
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 3, p. e0205477
...). Dipeptidyl dipeptidase-4 inhibitors (DPP-4 i) not only inhibit degradation of incretins to control blood glucose levels, but also improve EPC bioactivity and induce anti-inflammatory effects in tissues... 
RECRUITMENT | EFFICACY | SAFETY | INSULIN-RESISTANCE | MULTIDISCIPLINARY SCIENCES | BONE-MARROW | SITAGLIPTIN | INJURY | PEPTIDASE-4 INHIBITOR | DPP-4 INHIBITORS | FACTOR-I | Leukocytes, Mononuclear - metabolism | Endothelial Progenitor Cells - cytology | Obesity - drug therapy | Diet - adverse effects | Humans | Middle Aged | Male | Healthy Volunteers | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Young Adult | Adult | Obesity - etiology | Ischemia - pathology | Endothelial Progenitor Cells - metabolism | Leukocytes, Mononuclear - drug effects | Endothelial Progenitor Cells - drug effects | Mice, Inbred C57BL | Obesity - metabolism | Triazoles - pharmacology | Regeneration - drug effects | Animals | Ischemia - drug therapy | Hindlimb - drug effects | Leukocytes, Mononuclear - cytology | Mice, Obese | Mice | Ischemia - etiology | Care and treatment | Research | Regeneration (Biology) | Ischemia | Endothelium | Profiling | Cytotoxicity | Leukocytes (mononuclear) | Cardiovascular disease | Blood | Dipeptidase | Education | Research methodology | Bone marrow | Injury analysis | Medical research | Cytokines | Hyperlipidemia | Leukocytes (neutrophilic) | Beta cells | Injury prevention | Inhibitors | Diet | Perfusion | Stem cells | Cardiovascular diseases | Metabolic disorders | Methods | Lymphocytes T | Macrophages | Metabolic syndrome | Tissues | High fat diet | Granulocytes | Peripheral blood mononuclear cells | Diabetes mellitus (non-insulin dependent) | Hypertension | Diabetes mellitus | Blood cells | Health risks | Pharmacology | Inflammation | Chemical compounds | Progenitor cells | Biological activity | Medicine | Regeneration | Researchers | Cells (biology) | Microvasculature | Diabetes | Laboratory animals | Differentiation
Journal Article
Frontiers in immunology, ISSN 1664-3224, 2019, Volume 10, p. 1238
Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering skin disease that mainly affects the elderly. Typical clinical features include... 
IGG AUTOANTIBODIES | MORTALITY | gliptins | RETROSPECTIVE DATABASE | collagen XVII | diabetes mellitus | IMMUNOLOGY | IV INHIBITORS | DPP4 | bullous pemphigoid | COMORBIDITIES | DISEASE | CD26 | DPP-4 INHIBITORS | SKIN | BP180 | Autoimmunity | Medical research | Autoantibodies | Collagen | Bullous pemphigoid | Medicine, Experimental | Antigenic determinants | Usage | Proteases | Diagnosis | Research | Risk factors
Journal Article